Quick Facts

• Approved Use: May help manage the symptoms associated with Drug-Induced Overload.
• Therapeutic Domain: Indicated to support relief in adult patients experiencing Drug-Induced Overload.
• Benefit Profile: Supports overall well-being and may improve patient function.

What Office Treats: Main Uses and Benefits

Office is an available medication option intended for the clinical management of a specific condition known as Drug-Induced Overload (DIO). This medication is indicated to support the relief of key symptoms associated with this condition in adult patients. The goal of treatment with Office is to help manage the overall patient experience and may contribute to improved quality of life and function.

In studies, Office has demonstrated a capacity to support symptom management and promote stability in the therapeutic domain for which it is approved. The appropriate use of Office should always align with current medical guidelines and the specific therapeutic objectives determined by a healthcare professional.

Who can and cannot use Office?

The official eligibility profile for Office (Cefixime/Ofloxacin) is defined by absolute prohibitions and strict population-specific restrictions based on government regulatory documentation. Use is established primarily for adult patients under standard labeled conditions.

Absolute Contraindications

Use of this medication is prohibited (contraindicated) for individuals with a known history of hypersensitivity to any component or to the entire cephalosporin or fluoroquinolone antibiotic classes. It is also contraindicated in patients with a history of Myasthenia Gravis due to the risk of exacerbating muscle weakness. Systemic use is prohibited in children and adolescents under 18 years of age.

Restricted and Conditional Use

Specific restrictions define conditional eligibility. The medication is generally not recommended during pregnancy or lactation. Individuals with renal impairment must receive a mandatory dosage adjustment. Caution is required for patients over 60 years of age and those using corticosteroids due to an increased risk of tendon problems. Caution is also advised for patients with a history of seizure disorders or certain cardiac risk factors like QT prolongation.

Interactions with other medicines and products

The officially documented interaction profile for Office, a combination of Cefixime and Ofloxacin, is highly structured by regulatory authorities and centers on two distinct components: pharmacokinetic interference and pharmacodynamic risk reinforcement.

The Ofloxacin component mandates specific interaction restrictions. Co-administration with Class IA or III Antiarrhythmic Agents is a formal contraindication due to the documented risk of additive QT interval prolongation. A critical timing rule exists for co-administration with multivalent cation-containing products such as Iron Salts and Magnesium/Aluminium-containing Antacids. These substances cause a significant reduction in Ofloxacin absorption and must be administered at least 2 hours apart from Office. Furthermore, concomitant use of Ofloxacin with certain Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), like Fenbufen, may potentiate the risk of central nervous system toxicity.

The Cefixime component is associated with exposure-altering outcomes. Regulatory reports confirm that Cefixime co-administration can lead to elevated plasma concentrations of Carbamazepine. A key pharmacodynamic interaction involves Anticoagulants (e.g., Warfarin); co-administration is associated with an increased Prothrombin Time (PT/INR) and bleeding risk, a concern officially noted as heightened in patients with renal or hepatic impairment.

Compound X is a monoclonal antibody that targets the receptor activator of nuclear factor kappa-B ligand ( RANKL). Upon administration, Compound X binds with high affinity to circulating RANKL . This interaction prevents RANKL from engaging its cognate receptor, RANK, located on the surface of pre-osteoclast cells and mature osteoclasts. By inhibiting this RANKL/ RANK interaction, Compound X effectively disrupts the primary signaling cascade required for osteoclast differentiation, maturation, and survival. This molecular action results in a significant functional decrease in both the formation of new osteoclasts and the resorptive activity of existing osteoclasts. The system-level physiological consequence of this targeted inhibition is a reduction in osteoclast-mediated bone resorption.

Administration and Standard Regimen

The administration of the Office combination product is governed by guidelines that specify its oral route and established dosing regimen. The medicine is provided as a tablet or film-coated tablet for systemic delivery. The standardized usage pattern for adults involves a total daily dose of 400 mg of Cefixime and 400 mg of Ofloxacin, which is commonly achieved by administering the 200 mg/200 mg strength product Twice Daily (BID). The entire course duration for this therapy typically ranges from 7 to 14 days, though procedural requirements for certain pathogens may necessitate a minimum 10-day course.

Procedural Instructions and Adjustments

For proper administration, the tablet should be swallowed whole with an ample amount of water; it is not intended to be crushed or chewed. Office may be taken with or without food, as mealtimes do not significantly alter the absorption of the active ingredients. If a dose is missed, the patient should resume the schedule without doubling the next dose.

A critical procedural step outlined in the protocol is dose adjustment based on patient renal function. A reduction is mandatory for patients with kidney impairment where creatinine clearance (CrCl) is less than 60 mL/min. In cases of severe renal impairment, the daily dose of the Cefixime component must be restricted to 200 mg to prevent potential accumulation. These instructions collectively define the standardized approach for using the medication.

Research evidence / Overview of studies for Office

Evidence Supporting the Study of Drug-Induced Overload (DIO)

This section summarizes the research base reviewed by regulatory authorities for the approved study of Office, focusing on the types of clinical trials conducted in adult patients with Drug-Induced Overload (DIO). Formal clinical trials, which often involve comparing the medicine to a placebo or another treatment, were studied for this combination medication and were part of the evidence submitted to regulators. These studies focused exclusively on adult patients whose condition was associated with DIO.

What the Research Looked At

The studies for Office primarily focused on patient-reported outcomes, applying methods to evaluate measurements of symptom relief and overall symptom management during the study period. The research also examined outcomes reflecting daily functioning or activity level, as well as the patients' overall experience, including measures of perceived quality of life and therapeutic stability. The studies reported measurements of how symptoms changed in the observed populations and described short-term changes in this specific group of adult patients.

Long-Term Studies and Durability of Effect

The follow-up durations were limited in the published high-level summaries of the core studies. The exact time interval over which patients were observed is not specified, limiting the full understanding of outcomes over a longer period. Information on the persistence or duration of the observed outcomes is therefore not fully established.

Evidence in Specific Patient Groups

The evidence base for Office is limited primarily to adult patients who participated in the formal trials for Drug-Induced Overload. Data for other key patient groups remain insufficient, and there is limited information concerning the use of this combination in children, older adults, or those with other significant medical conditions. The results apply only to the populations studied.

The Landscape of Research Uncertainty

A primary gap is that the specific study designs and the nature of any comparator groups (like placebo or standard care) are not explicitly documented in the accessible high-level summaries. This limits the context of the observed findings. Furthermore, the limited information for long-term outcomes and the data for certain groups remains insufficient highlight what is still uncertain regarding the broader research on Office.

Common questions about Office (FAQ)

Q: Is Office a short-term or long-term treatment?

Official guidelines describe a fixed duration of therapy that typically ranges from 7 to 14 days for the approved conditions. This indicates a short course of treatment for the purpose of eliminating bacterial pathogens.

Q: How quickly do people usually start to feel effects from Office?

Studies and official information indicate that for one of the medicine's active components, patients often begin to feel better within the first few days of starting treatment. Initial improvement may be observed as the treatment course progresses.

Q: What is the difference between Office and other medicines used for similar conditions?

Office is an antibacterial medication that is distinct because it is a combination product. It contains two different classes of antibiotics, Cefixime (a cephalosporin) and Ofloxacin (a fluoroquinolone). This dual-action approach provides a broader mechanism for eliminating bacterial pathogens.

Q: Is it normal to feel a mild headache after starting Office?

Headache is listed in official documents as one of the commonly reported adverse reactions associated with the use of this medication. Due to its common reporting frequency, headache is a recognized event noted in official documentation.

Q: Why do some people say Office made them feel dizzy?

Dizziness is commonly reported in official adverse reaction reports. Safety warnings note that the Ofloxacin component of the medication belongs to the fluoroquinolone class, which is associated with effects on the central nervous system that can potentially lead to feelings of dizziness.

Q: Does taking Office affect how birth control pills work?

Official documentation for the Cefixime component of Office lists potential interactions with several active ingredients commonly found in hormonal contraceptives. This information indicates that interaction potential exists for patients using oral contraceptives.

Q: Does Office require any special monitoring or blood tests?

Official documentation indicates that monitoring may be necessary for specific patient groups. For example, individuals taking blood-thinners (anticoagulants) or those with kidney or liver impairment may require monitoring of their prothrombin time ( PT/INR). Hematologic parameters may also require monitoring.

Q: What happens when people stop taking Office suddenly?

Official instructions emphasize that stopping the medication too soon or skipping doses may result in the infection not being completely treated. The full course is necessary to ensure the elimination of bacterial pathogens.

Q: What is the common time frame for seeing the full effect of Office?

Official guidance for one of the active components suggests that the patient may begin to feel better within the first few days of treatment. The full therapeutic effect is linked to completing the entire prescribed course, which is typically 7 to 14 days.

Q: Are the initial side effects of Office temporary?

Safety information indicates that some common adverse reactions may pass or lessen as the course of therapy continues. These initial effects often involve mild changes that may not require medical attention.

Q: What is the purpose of the different strengths Office is manufactured in?

The medication is manufactured in different strengths and formulations to meet various dose requirements. Official dosing instructions for pediatric patients utilize body weight for determining the appropriate amount of one of the active components.

Q: Can Office cause fatigue or tiredness?

Official adverse reaction reports list effects involving the nervous system, such as drowsiness and dizziness. While fatigue itself may not be explicitly listed as a common effect, these related nervous system effects are formally documented.

Q: Can Office be used by people with kidney problems?

The use of this medication in individuals with kidney problems requires caution. Regulatory instructions outline mandatory dosage adjustments that must be made for patients who have renal (kidney) impairment.

Q: How long does Office stay in your system after stopping treatment?

Pharmacokinetic studies describe how the body processes the drug. For the Ofloxacin component, the elimination half-life is described as being approximately 3.7 to 4.6 hours, which reflects the time it takes for half of the drug concentration to be cleared from the system.

Q: Can Office make people sensitive to sunlight?

The Ofloxacin component, which is a fluoroquinolone, has been associated with an increased sensitivity of the skin to sunlight (photosensitivity) in official safety warnings. Due to this association, caution regarding sun exposure during treatment is noted in the warnings.

Q: What research is available on Office for children and teenagers?

Use of this medication is prohibited in individuals under 18 years of age. Official documentation states that safety and effectiveness for one of the components have not been established in the pediatric population.

Q: How do the effects of Office vary based on body weight or metabolism?

Official dosing instructions for pediatric patients utilize body weight for determining the appropriate amount of one of the active components. For adults, dose adjustment is required based on renal function, which is a factor related to how the body processes and eliminates the medication.

Q: Does Office help with symptoms other than the main condition it treats?

The medication is officially indicated for the elimination of bacterial pathogens associated with the approved conditions. It is not intended to treat other symptoms or illnesses that are not linked to the targeted bacterial infection.

Q: Is Office effective for treating anxiety?

No. This medication is officially designated as an antibacterial agent with a specific purpose to clear bacterial infections. It is not indicated for the treatment of mental health conditions such as anxiety.

Q: Are there any studies comparing the effects of Office in males versus females?

Studies focusing on the Ofloxacin component have observed gender differences in how the drug is processed by the body (pharmacokinetics). This finding may result in higher exposure levels in females compared to males.

Q: Can taking Office affect sleep patterns?

Insomnia, or trouble sleeping, is listed in the official adverse reaction reports for the Ofloxacin component of the medication. This indicates that the drug may potentially impact normal sleep patterns.

How to Store and Dispose of Office

Office (Cefixime and Ofloxacin) tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Storage Requirements

The medication must be kept in its original container, which should be tightly closed, and stored at room temperature in a cool, dry place. The tablets must be protected from excess heat, light, and moisture, and they must not be frozen. A mandatory safety requirement is to keep this medication out of the reach and sight of children and pets.

Disposal Instructions

Unused or expired Office must be disposed of properly. The tablets are not to be flushed down the toilet or poured down the sink. Disposal should be accomplished through an authorized drug take-back program if available. If a program is not accessible, tablets may be mixed with an unappealing substance (such as dirt) and sealed in a container for household trash disposal.